View Press Releases
-
CHARGEPOINT TECHNOLOGY APPOINTS NEW COO TO DRIVE FUTURE GROWTH
-
Birmingham Biotech and the University of Birmingham sign licensing agreement for anti-viral nasal spray against COVID-19
Birmingham Biotech Ltd, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, and the University of Birmingham have signed a licensing agreement to commercialise a novel anti-viral nasal spray that protects against COVID-19.
Nov 8, 2021
-
Protheragen MedAI Upgrades CADD Platform to Accelerate Drug Design
-
Samsung Biologics Reports Strong Second Quarter 2021 Financial Results
-
CluePoints partners with ZS to provide best-in-class RBQM expertise and technology, increasing clinical trial efficiency and improving patient outcomes
CluePoints, the premier provider of risk-based quality management (RBQM) and data oversight software for clinical trials, has partnered with ZS, a global professional services firm with technology and analytics expertise in biopharma, to offer innovative capabilities in portfolio-level performance oversight. The new partnership pairs a best-in-breed solutions company focused on study-level risk-based management with a pharmaceutical and biotech solutions provider with advanced capabilities in portfolio-level quality and operational oversight.
Aug 25, 2021
-
DFE Pharma Proudly Supports COVID-19 Vaccination Supply in Pakistan
-
Certara’s Simcyp™ COVID-19 Vaccine Model Named Finalist in Both the 2021 Citeline Awards and R&D 100 Awards
Certara’s Simcyp COVID-19 Vaccine Model uses biosimulation to improve decision-making and help optimize dosing regimens of COVID-19 vaccines. Certara calibrated its model using the structure of actual COVID-19 vaccines and validated it by replicating the published clinical data. The model, which is incorporated in Certara’s Vaccine Simulator™, addresses important questions such as differences in response with age and ethnicity, optimal timing between doses and expected duration of antibody response.
Aug 25, 2021
-
BOC Sciences Offers Pseudouridine and Its Derivatives for RNA Improvement
-
Biofourmis Earns FDA’s First-Ever Breakthrough Device Designation for a Novel Digital Therapeutic for Heart Failure
Biofourmis completed a proof of concept study for its heart failure digital therapeutic BiovitalsHF that met its endpoint of number of patients at 50% of optimal therapy. As a result, FDA has granted the DTx the first-ever Breakthrough Designation for a heart failure digital therapy.
Jul 29, 2021
-
Sensyne grows medical research dataset to 60 million patients
Deep longitudinal, disease agnostic structured global dataset, covering over 4,000 indications will industrialize Sensyne’s life sciences activities
Aug 1, 2021
-
Cisco fixes vulnerability that allowed criminals to remotely execute arbitrary code and control a firewall
Positive Technologies researchers discovered a vulnerability in Cisco Firepower Device Manager On-Box – a product designed to locally configure Cisco Firepower firewalls. Now patched, the flaw could allow attackers to gain full control over the device and its capabilities. That could include handing over to criminals the ability to filter traffic. Attackers could also shut down a firewall, or even access other internal resources within an enterprise, if they’re located on the same subnet.
Aug 1, 2021
-
Stelis Biopharma appoints Mark W. Womack as the new CEO
-
Amerigo Scientific Launches New AcrB Transporter for Therapeutic Indications
Amerigo Scientific recently launches AcrB transporter that aids in the identification, development, refinement, and validation of new molecules and therapeutic antibodies.
Aug 3, 2021
-
Advanced Instruments to Acquire Solentim, a Trusted Global Leader in Cell Imaging for Cell Line Development and Clone Characterization
Advanced Instruments, a leading manufacturer of analytical instruments and services for bioprocessing, today announced the execution of a definitive agreement to acquire Solentim, a trusted global leader of solutions for the isolation and characterization of high value single cell clones in cell line development (CLD) applications.
Aug 5, 2021
-
BIO-ISAC founded to protect and build resilience from increasing attacks on public and private bioeconomy infrastructure
-
DNAnexus Platform Exceeds Online Security Standards in President Biden’s Executive Order Aimed at Protecting American Infrastructure from Cyberattacks
DNAnexus platform exceeds online security policy objectives outlined in President Biden’s executive order protecting American infrastructure from cyberattacks
Aug 8, 2021
-
FDB Launches Clinical Decision Support Analytics Solution
FDB Launches Clinical Decision Support Analytics Solution
Aug 8, 2021
-
Lightbeam Health Solutions Announces Partnership with Genetic Testing Company, Ambry Genetics
Lightbeam Health Solutions Announces Partnership with Genetic Testing Company, Ambry Genetics
Aug 8, 2021
-
Heraeus completes multi-million Euro cancer therapy API capacity expansion
Heraeus Pharmaceutical Ingredients’ additional production line for Platinum-based highly potent active pharmaceutical ingredients (Pt hAPIs) is now fully operational at the company’s headquarters in Hanau, Germany.
Aug 9, 2021
-
Dotmatics to deliver the foundation for Croda’s R&D digital program: artificial intelligence and data mining
For further information on Dotmatics, please visit www.dotmatics.com
Aug 9, 2021